FDA Grants AP Status for Lenalidomide ANDA213912 by Mylan
The FDA has granted approval status (AP) for Mylan's abbreviated new drug application (ANDA) for lenalidomide.
Published: July 30, 2026
Updated: July 30, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Small Molecule
Company: Mylan
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mylan
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Mylan's ANDA for lenalidomide signifies a potential shift in the competitive landscape for this oncology drug. Pharma strategy teams must evaluate how this entry could affect market dynamics and pricing strategies for lenalidomide.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Mylan's timeline for market launch and any subsequent pricing strategies.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.